ndomyocardial biopsies (EMBs) are still the gold standard for establishing the diagnosis of myocarditis and cardiac virus persistence [1] [2] [3] [4] [5] [6] because anamnestic data and noninvasive diagnostic tools are not specific enough to ascertain myocardial virus persistence or inflammation. [7] [8] [9] [10] [11] [12] EMB-based diagnosis of myocarditis or cardiac virus persistence is gaining increasing relevance in clinical practice because controlled clinical trials have recently demonstrated beneficial effects of immunomodulatory therapies. [13] [14] [15] [16] [17] [18] [19] EMBs are also useful for assessing the clinical course and outcome of patients with impaired left ventricular (LV) function. 20 -23 Nevertheless, EMB procedures have not yet gained widespread acceptance because of concerns about possible complications associated with EMB procedures. Only small studies have been performed thus far on this topic; therefore, the risks of major complications caused by EMB procedures (eg, emergency cardiac surgery, cardiac tamponade requiring pericardiocentesis, or death) are still not well defined. 24 -26 
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The first report of a catheter-based bioptome was published in 1962. It was inserted through a peripheral vein (left basilic/axillary vein) or an artery (left axillary/common carotid artery) and advanced into the apex of the right ventricle (RV) or LV. 27 Over the years, the most common approach for EMB procedures has been through the right internal jugular vein, and the most common biopsy site was the RV side of the septum (interventricular septum [IVS] ) under fluoroscopic guidance, 24, 25 even if some groups used the LV as another biopsy site according to their personal experience. 2 Our single-center study analyzed the incidence of major and minor EMB procedure-related complications in a large database of 1919 retrospective and 496 prospective patients over an 11-year period. EMB procedures were performed by inserting a modified Cordis bioptome via the right femoral vein and taking EMBs from the RV septum under biplane fluoroscopic guidance without any additional echocardiographic control.
Methods

Patient Selection
In the retrospective part of our study, 1919 consecutive adult patients were enrolled over a period of 9 years (January 1995 to December 2003). In the prospective part, 496 patients were evaluated over a period of 2 years (January 2004 to December 2005). None of the patients was in a posttransplant setting. These patients underwent a total of 3048 EMB procedures over 11 years. An average of 8.2Ϯ0.8 EMBs were obtained retrospectively and 10.1Ϯ0.6 EMBs were obtained prospectively during each EMB procedure, yielding a total of 26 025 EMBs. EMB procedures were indicated for the evaluation of unexplained LV dysfunction, particularly in cases of clinically suspected myocarditis with progressive LV dysfunction, and for the evaluation of immunomodulatory treatment effects in viral myocarditis and inflammatory cardiomyopathy. EMBs were also taken from patients with unexplained ventricular arrhythmias, neoplastic heart disease, and systemic diseases with possible cardiac involvement according to the published recommendations. [2] [3] [4] [5] 28 Infiltrative or connective tissue disorders included amyloidosis, sarcoidosis, hemochromatosis, scleroderma, systemic lupus erythematodes, polyarteritis nodosa, dermatomyositis, polymyositis, mixed connective-tissue disease, and Wegener's granulomatosis.
After the clinical history and physical examination, we performed a 12-lead ECG, transthoracic echocardiography, chest x-ray, and selected laboratory tests (including liver and thyroid function tests and antinuclear antibodies measurement if indicated by the initial assessment) in all patients. All patients underwent coronary angiography to exclude coronary heart disease as a frequent cause of impaired LV function. LV dysfunction was evaluated by echocardiography and LV angiography, and LV end-diastolic pressure (LVEDP) was measured routinely. Patients with LV dysfunction and an identified secondary cause (ischemic or valvular heart disease, hypertension, peripartum cardiomyopathy, drug abuse, endocrine diseases like thyroid disease, diabetes, pheochromocytoma, or neuromuscular disease) were excluded from further EMB procedure diagnostics.
In patients with myocardial virus genomes or inflammation proven by EMB diagnostics, follow-up biopsies were obtained to evaluate the course and the effect of immunomodulatory treatment strategies (interferon-␤, prednisone, and azathioprine). [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] 
Definition of Major Complications and Minor Complications
Major Complications
Major complications included death, urgent cardiac surgery, advanced cardiac life support, pericardiocentesis in cardiac tamponade, permanent complete atrioventricular (AV) block requiring permanent pacing, hemothorax, and pneumothorax.
Minor Complications
Minor complications included pericardial effusion without pericardiocentesis, temporary (lasting Ͻ24 hours) or permanent right bundle-branch block (RBBB), temporary Mobitz type II AV block with AV conduction 2:1 requiring medical treatment with atropine, complete AV block requiring medical treatment with atropine or additive temporary pacing, nonsustained ventricular tachycardia with long runs of Ն10 ventricular complexes, and an episode of atrial fibrillation lasting Ͻ12 hours or cardioversion of atrial fibrillation.
EMB, Right Heart Catheterization, and Echocardiography EMB procedures were limited to 4 highly experienced operators with Ͼ800 invasive procedures a year over a period of at least 5 years. Interventional fellows performed at least 50 EMB procedures per year, and senior clinicians performed Ͼ100. Operators were only allowed to perform EMB procedures alone if a minimum of 50 procedures had been previously supervised by a senior operator. Patients had to have an international normalized ratio of Ͻ1.5 at the time of EMB procedures, and anticoagulant therapy with phenprocoumon or heparin was discontinued for 16 hours before and 12 hours after EMB procedures. EMB procedures were performed with the use of a modified Cordis bioptome. This bioptome (B-18110; Medizintechnik Meiners, Monheim, Germany) has been used in clinical practice since 1985. It has a 6F diameter and a total length of 1100 mm. The 2 closed bioptome jaws have a total diameter of 1.8 mm, a length of 2.8 mm, and a volume of 4.5 mm 3 . Compared with the Cordis bioptome, it has a more flexible polytetrafluoroethylene (Teflon) tube instead of an inflexible steel spiral as well as smaller jaws at the bioptome head.
Vascular access was obtained via the right femoral vein under local anesthesia with 2% lidocaine. The bioptome was advanced slowly up to the middle to apical segment of the right IVS under biplane fluoroscopic guidance. Once contact with the IVS was confirmed by premature ventricular complexes, the bioptome was withdrawn 1 to 2 cm, and its jaws were opened and slowly advanced to engage the IVS. Gentle forward pressure was maintained while the jaws were closed. The bioptome containing the specimen was removed by gentle traction on the shaft. Right heart filling pressures (including RV end-diastolic pressure [RVEDP]) were measured with a pigtail catheter before and after EMB procedures for the early detection of an incipient cardiac tamponade. A 12-lead ECG and a standard transthoracic 2-dimensional and M-mode echocardiography were performed in all patients before EMB procedures. LV diastolic (LVEDD) and systolic (LVESD) dimensions were measured by M-mode echocardiography by the leading-edge method in the parasternal long-axis view. In the retrospective trial, all patients developing chest pain, dyspnea, or ECG changes after the EMB procedures received a control echocardiography to detect pericardial effusion or incipient cardiac tamponade. In the prospective trial, all patients underwent a 12-lead ECG and a transthoracic echocardiography after EMB procedures to obtain a detailed evaluation of the incidence of conduction abnormalities, arrhythmias, and pericardial effusions. In addition, a detailed worksheet was filled out for all patients for every examination during their further clinical workup, on which all adverse EMB procedure-related events were immediately recorded. Abnormalities and respective changes before and after EMB procedures were documented by ECG and echocardiography findings. Such findings included a new onset of atrial fibrillation, ventricular tachycardia, RBBB, left bundle-branch block (LBBB), conduction abnormalities requiring atropine, other antiarrhythmic agents administered intravenously, and temporary versus permanent pacing. Correspondingly, a new onset of pericardial effusion was documented after echocardiography. Complications like death, urgent cardiac surgery, advanced cardiac life support, pericardiocentesis, hemothorax, and pneumothorax were also documented.
Statistical Analysis
Mean values and SD were calculated with Microsoft Excel Office 2000 software (Microsoft Corporation, Redmond, Wash). Two sample tests for equality of proportions were performed for the subgroups of EMB procedures in patients with enlarged LV or preexisting LBBB as a risk factor for major complications with the use of the Fisher exact test in SAS (version 9.1) (SAS Institute Inc, Cary, NC) for a small number of events. A probability value of Ͻ0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed to the manuscript as written.
Results
Patient Characteristics
All adult patients enrolled in the retrospective (nϭ1919) and prospective study (nϭ496) had global LV dysfunction with an ejection fraction (EF) of Ͻ50% or regional LV dysfunction with wall motion disturbances in Ն2 wall segments. The baseline characteristics of the study patients with detailed clinical and hemodynamic data are listed in Table 1 .
Major Complications in 2505 Retrospective EMB Procedures
Cardiac Perforation Cardiac perforation was seen in 2 cases (0.08%) ( Table 2) . These 2 patients developed symptoms of chest pain, dyspnea, bradycardia, and a decrease in systolic pressure to Ͻ70 mm Hg accompanied by an increase in right heart filling pressures during myocardial biopsy. Echocardiography revealed the presence of pericardial effusion with RV collapse indicating cardiac tamponade due to RV free wall perforation. Immediate pericardiocentesis with the standard subxiphoidal percutaneous access rapidly improved the hemodynamic status of both patients. The pigtail catheter placed in the pericardial space was removed after 18 or 26 hours, respectively, when there was no further drainage. One of these 2 patients with a final diagnosis of dilated cardiomyopathy developed hemodynamically relevant bradycardia requiring temporary pacing before pericardiocentesis was started. In this case, the pacemaker could be removed after 7 minutes. The second patient had a final diagnosis of an angiosarcoma with diffuse pleural, pericardial, epicardial, and myocardial metastases. The clinical follow-up of both patients showed no long-term sequelae. Interestingly, both cases of cardiac tamponade during EMB procedures occurred in patients with normal LV dimensions (LVEDD Յ65 mm).
Conduction Abnormalities
Only 1 (0.04%) of the 5 patients requiring temporary pacing (see Minor Complications) needed a permanent pacer because of persistent conduction abnormalities (Table 2) . She had a preexisting LBBB and known scleroderma with predominant dermatological and limited pulmonary manifestations. The EMBs demonstrated significant interstitial and subendocardial fibrosis and degenerative atrophy with consecutive hypertrophy of heart muscle cell groups. Hence, the EMBs confirmed the diagnosis of a cardiac manifestation of scleroderma, and specific therapy was started with D-penicillamine in addition to an angiotensin-converting enzyme inhibitor. This patient also had no relevant LV enlargement (LVEDD Յ65 mm).
Other Major Complications
There was no EMB procedure-related death, no case requiring emergency cardiac surgery, and no case of pneumothorax or hemothorax (Table 2) .
Minor Complications in 2505 Retrospective EMB Procedures
Conduction Abnormalities
Altogether, 5 cases (0.20%) developed complete AV block during the EMB procedures, which required temporary pacing because of hemodynamic instability (Table 3) . The aforementioned patient with cardiac perforation developed bradycardia with hemodynamic instability before pericardiocentesis. Another patient developed complete AV block In all performed EMB procedures, patients with preexisting LBBB had a significantly higher risk of developing a temporary complete AV block requiring temporary pacing than those without LBBB (Fisher exact test, Pϭ0.02; Table  4 ). Subgroup analyses demonstrated an increased incidence of temporary pacing in patients with normal LV dimensions (LVEDD Յ65 mm, 0.21% versus 0.17%).
Major Complications in 543 Prospective EMB Procedures
There was no case of EMB procedure-related pericardial tamponade requiring pericardiocentesis, no pneumothorax or hemothorax, no permanent pacemaker support, no death, and no case requiring emergency cardiac surgery (Table 2) .
Minor Complications in 543 Prospective EMB Procedures
Pericardial Effusions
There were 4 cases (0.74%) of EMB procedure-induced small pericardial effusions, 3 with de novo onset after EMB procedures and 1 with an increase of the preexisting effusion ( Table 2) . None of the patients experienced hemodynamic impairment, and all cases resolved spontaneously within 4 days. There was no evidence of microperforation in any EMB by histological assessment; in particular, no mesothelial cells or nerve tissues were detected.
Conduction Abnormalities
Conduction abnormalities such as RBBB induced during the EMB procedures were temporary (lasting Ͻ24 hours after EMB procedures) in 6 cases (1.10%) and sustained (Ͼ24 hours) in 2 cases (0.37%). Furthermore, we documented periprocedural Mobitz type II AV block with 2:1 AV conduction in 2 cases (0.37%) and complete AV block in 2 cases (0.37%), all requiring atropine 0.5 to 1 mg and resolving spontaneously within 10 minutes. Temporary AV block III requiring injection of atropine 0.5 to 1 mg and temporary pacemaker support occurred in 8 cases (1.47%), with the period of temporary pacing ranging from 22 seconds to 4 hours (mean pacing time of 66.3Ϯ8.8 minutes).
All of these 8 patients had preexisting LBBB. Patients with preexisting LBBB had a significantly higher risk of developing temporary complete AV block requiring temporary pacing (9.64%) than those without LBBB (Fisher exact test, PϽ0.01; Table 4 ). Subgroup analysis demonstrated an increased incidence of temporary pacing in patients with normal LV dimensions (LVEDD Յ65 mm, 1.7% versus 0.78%).
Arrhythmias
There were no cases of complex ventricular arrhythmias such as nonsustained ventricular tachycardia with long runs of Ն10 ventricular complexes, 5 (0.92%) episodes of atrial fibrillation (lasting Ͻ12 hours), and 1 case (0.18%) of persistent atrial fibrillation (lasting Ͼ12 hours) with subsequent successful cardioversion. The clinical follow-up of all these patients showed no long-term sequelae.
Discussion
This is the largest report of 3048 EMB procedures, analyzing major and minor complications of this invasive procedure. Nonsustained ventricular tachycardia (Ն10 ventricular complexes)
Persistent atrial fibrillation with cardioversion
Holzmann et al Complication Rate in Endomyocardial Biopsy
The patients (1919 retrospectively and 496 prospectively investigated) were unselected adults in a nontransplant setting, and all RV EMB procedures were performed by the right femoral vein approach with a modified Cordis bioptome. The risk of major complications in this single-center study was very low: 0.12% when analyzed retrospectively and 0% prospectively. In the retrospective trial, 2 patients required pericardiocentesis because of cardiac tamponade (0.08%), and 1 patient required a permanent pacemaker because of persistent complete AV block after the EMB procedures (0.04%). When we compared these data with the major complication rates of EMB procedures reported by 2 earlier monocentric studies, the rate of major complications in our study was lower. Deckers et al 24 performed a prospective study on the complication rate of 546 EMB procedures in 464 patients between 1982 and 1989. They reported a major complications rate including death of 0.37%, caused by cardiac tamponade despite pericardiocentesis. Patients in this study had a lower mean LVEF and higher filling pressures compared with the patients in our study. The difference in major complications (death, urgent cardiac surgery, advanced cardiac life support, pericardiocentesis, permanent pacemaker implantation, hemothorax, and pneumothorax) despite similar perforation rates in both studies (0.7% small pericardial effusion in this prospective analysis and 0.5% in the Deckers analysis) may arise from the fact that seriously ill patients have only a small margin for further hemodynamic problems due to perforation. From the same center, Felker et al 25 reported on a prospective analysis of 323 EMB procedures between January 1996 and September 1998 with an incidence of 0.31% of cardiac tamponade requiring urgent cardiac surgery. A similar rate of emergency surgery of 0.27% was reported by Frustaci et al 2 in a subanalysis of RV free wall perforations occurring during 1481 RV EMB procedures.
There are several possible reasons for this difference in the major complication rate between our study and the 2 earlier ones. We exclusively used the right femoral vein for vascular access instead of the right internal jugular vein as in the other studies, and EMBs were only obtained from the RV septum. An obvious advantage of the femoral approach is the absence of any risk of pneumothorax or hemothorax. Furthermore, a modified Cordis bioptome, which is more flexible and less traumatic, was used under biplane fluoroscopic control.
Another reason for the low complication rate in our study may be the high level of experience of the operators performing EMB procedures in our center. Only a very small number (nϭ4) of interventional fellows and senior clinicians performed EMB procedures, and these operators had a high level of experience in interventional cardiology with Ͼ800 invasive procedures annually over a period of at least 5 years. In addition, these operators had initially been trained by senior clinicians with extensive EMB procedure experience and Ͼ100 EMB procedures per year. Operators were only allowed to perform EMB procedures alone if a minimum of 50 EMB procedures had been previously supervised by a senior operator.
When we compared the rate of minor complications in our study, it was much lower retrospectively (0.20%) than prospectively (5.5%). This is apparently due to the introduction of a detailed worksheet for each patient covering all minor complications in the prospective trial. Furthermore, an echocardiogram was then routinely performed in each patient before and after the EMB procedures to detect any EMB procedure-associated minor pericardial effusion independent of subjective complaints or hemodynamic measurements. Despite this very detailed documentation of all possible complications in the prospective trial, we observed no complication with severe sequelae for the patients. The studies of Deckers et al 24 25 In our study, the rate of pericardial effusion resolving spontaneously was 0.7%, which is similar to the rates reported by Frustaci et al 2 (0.4%) and Deckers et al 24 (0.5%). Conduction abnormalities (RBBB, temporary Mobitz type II AV block, or temporary AV block III, treated medically or additionally requiring temporary pacing) were more frequent in our study (3.7%) than in the studies of Deckers (0.9%) and Felker (0.6%).
Possible explanations for the increased incidence of conduction abnormalities in our prospective study include the different right femoral vein approach and the fact that our patients had only mildly reduced EF and near-normal cardiac dimensions. Under these conditions involving a more acute angle between the inferior vena cava and the longitudinal axis of the tricuspid valve, it is sometimes more difficult to advance the bioptome via the femoral approach through the relatively small cardiac spaces to an adequate position for EMBs in the middle to apical region of the IVS. The occasional need to more intensely manipulate the bioptome under these conditions may cause increased irritation at the basal IVS close to the right bundle branch and AV node and thus induce conduction abnormalities more frequently.
To test this hypothesis, we analyzed subgroups of our patients with major LV dilation (LVEDD Ͼ65 mm). The risk of conduction abnormalities requiring temporary pacing was linked in both the retrospective and the prospective studies to normal LV dimensions (LVEDD Յ65 mm; 0.21%/1.7%). Patients with LV dilation showed a trend toward a lower incidence of temporary pacing requirement (0.17%/0.78%), which was, however, not significant.
To evaluate the impact of preexisting LBBB as a risk factor for developing conduction abnormalities during EMB procedures, we performed an analysis of a patient subgroup with preexisting LBBB (Table 4 ). The risk of developing temporary complete AV block requiring temporary pacing induced by EMB procedures was significantly increased by preexisting LBBB, with 0.84% in the retrospective and 9.64% in the prospective part of our study (PϽ0.01). Mechanical irritation of the right bundle branch is apparently sufficient to induce temporary complete AV block in patients with a preexisting LBBB.
Conclusions
When performed by experienced operators, the EMB procedure from the RV septum via the right femoral vein approach under biplane fluoroscopic guidance is a safe procedure for evaluating patients with unexplained LV dysfunction. Major complications were very low in both the retrospective and prospective trials (0.12% versus 0%). Patients with preexisting LBBB had a significantly higher risk of developing complete AV block requiring temporary pacing. Patients with LV enlargement had no increased risk of conduction abnormalities requiring temporary pacemaker support.
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